Pith. sign in

REVIEW 14 cited by

DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2411.15692 v2 pith:IVKTSKIN submitted 2024-11-24 cs.LG

DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration

classification cs.LG
keywords discoverydrugdrugagentideasmulti-agentprogrammingtasksaccelerating
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
Share X Bluesky LinkedIn Reddit HN
read the original abstract

Recent progress in Large Language Models (LLMs) has drawn attention to their potential for accelerating drug discovery. However, a central problem remains: translating theoretical ideas into robust implementations in the highly specialized context of pharmaceutical research. This limitation prevents practitioners from making full use of the latest AI developments in drug discovery. To address this challenge, we introduce DrugAgent, a multi-agent framework that automates machine learning (ML) programming for drug discovery tasks. DrugAgent employs an LLM Planner that formulates high-level ideas and an LLM Instructor that identifies and integrates domain knowledge when implementing those ideas. We present case studies on three representative drug discovery tasks. Our results show that DrugAgent consistently outperforms leading baselines, including a relative improvement of 4.92% in ROC-AUC compared to ReAct for drug-target interaction (DTI). DrugAgent is publicly available at https://anonymous.4open.science/r/drugagent-5C42/.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 14 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. Scalable Agentic Reasoning for Designing Biologics Targeting Intrinsically Disordered Proteins

    q-bio.QM 2025-12 unverdicted novelty 7.0

    StructBioReasoner is a scalable multi-agent system that designs IDP-targeting biologics, with over 50% of 787 candidates for Der f 21 showing better binding free energy than human-designed references.

  2. Inside the Unfair Judge: A Mechanistic Interpretability Account of LLM-as-Judge Bias

    cs.LG 2026-07 conditional novelty 6.5

    LLM-as-judge scoring biases concentrate in low-dimensional, type-specific activation subspaces that support bidirectional causal steering and cross-domain failure prediction.

  3. Studying quantization trade-offs for efficient inference deployment in machine translation

    cs.CL 2026-07 conditional novelty 6.0

    Quantized Hy-MT2 models stay accurate at long context, but quantized EuroLLM 9B/22B models collapse (up to ~60% chrF++ drop) while W4A8/W8A8 plus 200–400-token chunking improves serving throughput.

  4. Studying quantization trade-offs for efficient inference deployment in machine translation

    cs.CL 2026-07 conditional novelty 6.0

    Combining 200-400 token document chunking with W4A8/W8A8 quantization improves MT serving efficiency, while long-context translation quality collapses for quantized EuroLLM but not for quantized Hy-MT2.

  5. A Precedent-Guided Co-Scientist for Side-Effect-Aware Drug Redesign

    cs.LG 2026-07 conditional novelty 6.0

    PRECEDE redesigns parent drugs to mitigate a specified side effect by classifying liability mechanism, transferring strategies from historical precedents, and ranking candidates with in silico proxies under human checkpoints.

  6. Closed-loop Auto Research for Molecular Property Prediction: Discovering and Certifying Generalizable Improvements

    cs.AI 2026-06 unverdicted novelty 6.0

    Closed-loop LM-agent auto research finds some transferable gains on molecular property prediction benchmarks via external data but shows non-transfer for model and feature edits selected on validation.

  7. Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization

    cs.AI 2026-04 unverdicted novelty 6.0

    DrugKLM integrates knowledge graphs and LLMs to prioritize mechanistically plausible drug repurposing candidates, outperforming baselines and aligning scores with improved survival signatures in cancer data.

  8. MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

    cs.AI 2026-04 unverdicted novelty 6.0

    MolClaw deploys a hierarchical skill system (tool, workflow, and discipline levels) to achieve state-of-the-art results on MolBench tasks requiring 8 to 50+ sequential tool calls in drug discovery.

  9. IR-Agent: Expert-Inspired LLM Agents for Structure Elucidation from Infrared Spectra

    cs.AI 2025-08 unverdicted novelty 6.0

    IR-Agent is a multi-agent LLM framework that emulates expert IR spectral analysis procedures to improve molecular structure elucidation accuracy and adaptability.

  10. GenoMAS: A Multi-Agent Framework for Scientific Discovery via Code-Driven Gene Expression Analysis

    cs.AI 2025-07 unverdicted novelty 6.0

    GenoMAS deploys six specialized LLM agents with guided planning to preprocess transcriptomic data and identify genes, reaching 89.13% composite similarity and 60.48% F1 on the GenoTEX benchmark while outperforming pri...

  11. Evaluating Agentic Bioinformatics through Function, Evidence, and Validation

    cs.AI 2026-07 conditional novelty 5.0

    Agentic bioinformatics systems mostly demonstrate planning and tool execution but rarely prospective empirical validation, so the paper argues evaluation should center on inspectable workflow trajectories (FEV) rather...

  12. MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

    cs.AI 2026-04 unverdicted novelty 5.0

    MolClaw deploys a hierarchical skill architecture to reach state-of-the-art results on a new benchmark of multi-step drug discovery tasks.

  13. DrugPlayGround: Benchmarking Large Language Models and Embeddings for Drug Discovery

    cs.LG 2026-02 unverdicted novelty 5.0

    DrugPlayGround is a new benchmark framework for evaluating LLMs on text-based descriptions of physiochemical drug characteristics, synergism, drug-protein interactions, and physiological responses.

  14. Valid Property-Enhanced Contrastive Learning for Targeted Optimization & Resampling for Novel Drug Design

    cs.LG 2025-08 conditional novelty 5.0

    VECTOR+ combines contrastive learning and Gaussian mixture sampling to generate novel, synthetically plausible inhibitors from low-data datasets, with improved docking scores over known compounds.